000963 华东医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入31,477,6553.56%40,623,78337,714,58734,563,30133,683,059
减:营业总成本28,288,8122.72%37,081,91534,568,57031,727,33630,666,230
    其中:营业成本21,231,8032.51%27,461,73225,682,49723,957,37122,550,482
               财务费用38,018-40.63%51,19078,25722,07534,201
               资产减值损失----(6,520)(3,822)(16,908)(4,538)
公允价值变动收益----(13,756)28,469----
投资收益(86,710)-48.64%(219,713)(141,560)(96,312)(27,525)
    其中:对联营企业和合营企业的投资收益(54,563)-62.45%(188,391)(115,619)(53,433)(10,826)
营业利润3,215,35218.71%3,452,9273,061,4542,855,7143,476,575
利润总额3,133,88416.58%3,465,9863,031,1242,827,5353,453,391
减:所得税费用571,27915.51%619,589498,499488,907543,674
净利润2,562,60416.82%2,846,3972,532,6262,338,6282,909,717
减:非控股权益278-93.83%7,53633,41136,99689,855
股东净利润2,562,32717.05%2,838,8612,499,2142,301,6312,819,861

市场价值指针
每股收益 (元) *1.46417.06%1.6221.4281.3151.612
每股派息 (元) *0.350--0.5800.2900.2900.230
每股净资产 (元) *12.5648.60%11.99710.5929.4758.355
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容